CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
Rifabutindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002267
NCT00002267N/ACompleted
CompareCT.gov

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

Pharmacia·interventional·Posted Aug 31, 2001·Updated Jun 24, 2005

In Brief

A clinical study evaluating Rifabutin for Mycobacterium Avium-intracellulare Infection and HIV Infections. Completed, across 43 sites in 2 countries.

Detailed Summary

The primary objective of this trial is to assess the safety and the relative benefit of rifabutin monotherapy in preventing or delaying the incidence of Mycobacterium avium complex (MAC) bacteremia in AIDS patients with CD4 counts less than or equal to 200, as compared to placebo, and to assess if survival is prolonged in patients who receive rifabutin prophylaxis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMycobacterium Avium-intracellulare Infection, HIV Infections
CountriesCanada, United States
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Rifabutindrug